Baxter International Inc. reports news on its global medtech business, which supplies hospitals, physician offices and other care settings with connected solutions, medical devices and advanced injectable technologies. Company updates commonly cover results from continuing operations following the Kidney Care divestiture, portfolio activity in infusion therapies and platforms, surgical tables, smart stretchers, patient-support systems, monitoring tools, and hemostatic and sealing agents.
Baxter announcements also address product introductions such as the IV Verify Line Labeling System, conference showcases for Global Surgical Solutions, Advanced Surgery and Patient Support Systems, annual-meeting matters, executive finance leadership, and foundation partnerships tied to healthcare settings.
Baxter International Inc. (NYSE:BAX) has declared a quarterly cash dividend of $0.28 per share, payable on April 1, 2022, to shareholders recorded by February 25, 2022. This brings the annual dividend rate to $1.12 per share. As a leading medtech company, Baxter continues to support patients and healthcare providers globally with innovative products across various medical sectors.
Baxter International Inc. (NYSE:BAX) will present at Citi's 2022 Virtual Healthcare Conference on February 23, 2022, at 1:15 p.m. Eastern Time. Chief Financial Officer Jay Saccaro is scheduled to deliver the presentation. A live webcast will be accessible at www.baxter.com and can be replayed until February 22, 2023.
Baxter provides crucial healthcare solutions, operating in over 100 countries for nearly 90 years. They focus on advancing innovative healthcare products and therapies.
Baxter International and the Thurgood Marshall College Fund have launched the Baxter HBCU STEM Scholars Program, a $3.5 million initiative aimed at supporting students from Historically Black Colleges and Universities (HBCUs) in STEM fields. The program will offer scholarships and mentorship to approximately 40 students over three years, addressing the low graduation rates among Black students (44% compared to 63% overall). The initiative also enhances teacher retention through mentorship for Black and Brown educators.
Baxter International Inc. (NYSE:BAX) will conduct a conference call on February 17, 2022, at 7:30 a.m. Central Time, to discuss its fourth-quarter 2021 financial results. Interested participants can pre-register via the provided link. This call will also be webcast on Baxter's website. Baxter provides a wide range of medical products and services in over 100 countries, focusing on critical care, kidney care, and surgical products. The company aims to leverage its legacy to drive innovation in healthcare.
Baxter International Inc. (NYSE:BAX) has completed its acquisition of Hillrom for $10.5 billion, paying $156 per share in cash. This transaction aims to enhance Baxter's healthcare transformation vision and is expected to generate approximately $250 million in annual pre-tax cost synergies by the end of year three. The acquisition is projected to positively impact Baxter's adjusted earnings per share, expanding margins and cash flow generation, with high single-digit returns on invested capital anticipated by year five. The combination will also enhance product accessibility globally.
Baxter International Inc. (NYSE:BAX) announced findings from a study suggesting that machine learning and AI can enhance medication safety in hospitals. Conducted with MedAware, the research analyzed over 3.8 million infusions and found that AI could assist in adjusting Dose Error Reduction Systems (DERS) to reduce medication errors. The results indicated that 52% of outliers triggered hard limits, showcasing the need for better DERS limits. The study was presented at the ASHP 2021 Midyear Clinical Meeting, highlighting advancements in infusion pump technology for patient safety.
Summary not available.
Baxter International Inc. (NYSE:BAX) has declared a quarterly cash dividend of $0.28 per share, payable on January 3, 2022, to shareholders recorded as of December 3, 2021. This dividend reflects an annual rate of $1.12 per share. The announcement emphasizes the company's commitment to returning value to its shareholders through consistent dividend payments.
Summary not available.
Baxter International Inc. (NYSE:BAX) has announced a significant investment of approximately $100 million to expand its sterile fill/finish manufacturing facility in Halle/Westfalen, Germany. This expansion will enhance production capabilities with a new syringe filling line and increased vial capacity, aimed at improving product stability and shelf life via lyophilization. The construction is set to start in 2022 and be completed by 2024, positioning Baxter to meet rising demand for injectable pharmaceuticals across Europe and the United States.